Navigation Links
New Drug Shows Promise Against Huntington's Disease
Date:11/7/2011

MONDAY, Nov. 7 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.

Huntington's patients have an imbalance in the signaling chemical dopamine. The new drug stabilizes dopamine signaling in areas of the brain that control movement and coordination.

According to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily. The only drug currently approved for Huntington's is tetrabenazine, which treats only involuntary movements and can cause serious side effects.

The results of the phase 3 clinical trial, conducted by Spanish researchers led by Dr. Justo Garcia de Yebenes, of the department of neurology, Hospital Ramon y Cajal in Madrid, appear in the Nov. 7 online edition of The Lancet Neurology.

The study included 437 Huntington's disease patients from eight European countries. The participants took either pridopidine (45 milligrams once daily or 45 mg twice daily) or a placebo for 26 weeks.

After six months of treatment, patients taking the higher dose of pridopidine showed improvements in motor function -- specifically in eye and hand movements, involuntary muscle contractions (dystonia), and gait and balance -- compared with patients taking the placebo.

More than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers. Side effects among patients taking the drug were similar to the placebo group.

"Pridopidine has the potential to complement available treatments by improving a different range of motor deficits. Its lack of severe side-effects . . . suggests that pridopidine might be useful even for those patients who are treated at sites that are not centers of excellence for Huntington's disease," the researchers concluded.

One U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.

"There has been a great deal of attention for this drug, as it is one of the few molecules that in preliminary studies was found to have some efficacy in Huntington's disease," said Dr. Alessandro Di Rocco, professor in the department of neurology and chief of the division of movement disorders at NYU Langone Medical Center in New York City.

"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease. And, though the compound is apparently well tolerated without significant side effects, the benefit is modest and limited to the motor symptoms of the disease and it is unknown how long the improvement observed could last," he added.

Still, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.

"Unfortunately, Huntington's is a progressive disease and this drug is not a treatment of the disease itself but only improves some of its symptoms," he explained. "Nevertheless, it is a welcome addition because there is very little else yet available to treat the symptoms. The challenge for scientists and clinicians is to discover therapies that actually slows or halts the progression of the disease."

Another expert agreed that new treatment options for patients are sorely needed.

"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder," Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.

The study was funded by European pharmaceuticals company NeuroSearch A/S.

More information

We Move has more about Huntington's disease.

-- Robert Preidt

SOURCES: Alessandro Di Rocco, M.D., professor, department of neurology and chief, division of movement disorders, NYU Langone Medical Center, New York City; The Lancet Neurology, news release, Nov. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene therapy shows promise as hemophilia treatment in animal studies
2. Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, UB study shows
3. New drug shows promise against multiple sclerosis
4. Preterm birth rate shows three year improvement in most states
5. Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation
6. Novel approach to treat proliferative vitreoretinopathy shows promise
7. New therapy shows promise for treating cardiovascular disease
8. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
9. New oncolytic virus shows improved effectiveness in preclinical testing
10. Clinical trial shows first evidence that anal cancer is preventable
11. Through-the-nipple breast cancer therapy shows promise in early tests
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Shows Promise Against Huntington's Disease
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... 17, 2017 , ... A recent report indicates that circa 79 percent of ... deficiencies in data integrity. The FDA outlines their expectations for quality critical instrumentation in ... part of the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo Valley ... who successfully complete the seven-week long Patient Care Academy are eligible to take the ... salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one is ...
(Date:8/16/2017)... ... August 16, 2017 , ... Greenfield Advisors is honored to be named to ... second year in a row. The Inc. 5000 list honors private businesses across the ... on the list once is a great accomplishment, but for us to be included ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Any ... Inc. 5000. The company ranked #4429 on the newly released, 36th annual Inc. ... represents a unique look at the most successful companies within the American economy’s most ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
Breaking Medicine Technology: